Trastuzumab deruxtecan plus pertuzumab ‘nearly doubles’ disease control in breast cancer

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive metastatic breast cancer.Interim results from the DESTINY-Breast-09 trial, presented at ASCO Annual Meeting, suggest trastuzumab deruxtecan (T-DXd; Enhertu; AstraZeneca, Daiichi Sankyo) plus pertuzumab

Read the full article here

Related Articles